Takeda’s U.S. Approval For Alogliptin Boosts Prospects Of Contrave And TAK-875
This article was originally published in PharmAsia News
Executive Summary
With a reenergized metabolic infrastructure, Takeda can otherwise “digest” its acquisition of Nycomed, because no transformative deals are in near sight.